Life Science Hub
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns
Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
The Silent Trigger: How Biotome is Dismantling the World’s Fourth Deadliest Cancer
Biotome is transforming gastric cancer detection through precision immunology. Their flagship test Helitope uses peptide augmentation to target specific bacterial markers, delivering 10 times greater sensitivity and 95% accuracy compared to traditional diagnostic tests.
The Endocannabinoid Entrepreneurs: Inside Medigrowth’s Mission to Mainstream Plant-Based Medicine
Medigrowth is transforming the Australian cannabis landscape from a “wild west” into a clinically-led biotech powerhouse. Led by founders Adam Guskich and Todd McClellan, the company is leveraging university-led research to target a multi-billion dollar unmet need in chronic conditions including pain and mental health.
Vision Via Sound for the Blind: Can a Silicon Valley Veteran Deliver the Solution to a $2B NDIS Problem?
Serial entrepreneur Robert Yearsley is trading pixels for perception with ARIA Research, a Sydney-based deep-tech company using “augmented reality in audio” to help the blind perceive the world. By bypassing traditional bionics in favour of real-time 3D soundscapes, ARIA is tackling a multi-billion dollar unmet need in the global disability sector and redefining what it means to “see” without eyesight.
Every Breath Matters: A Melbourne Startup Solving a Long-Standing Clinical Need in Neonatal Care
A Forbes 30 Under 30 team has developed Ventora Medical, a company solving the critical “blind spot” in neonatal care. By embedding a high-precision sensor technology into enteral feeding tubes , their Airway Pressure Monitor provides real-time data, significantly reducing the 40% failure rate of non-invasive breathing support for premature babies and getting families home sooner.
Targeting the Untouchable: The High-Stakes Race to Outsmart ‘Invisible’ Tumors
Percheron Therapeutics is developing the drug HMBD-002 to target the VISTA protein, aiming to make previously “invisible” cancers visible to the immune system. The company is preparing for its critical Phase 2 human trials in 2026 after successful Phase 1 results showed tumor shrinkage.
Backed By Leading Investment Groups and Family Offices
